Online Letters to the EditorThe authors replyRogers, Angela J. MD, MPH; Desai, Menisha PhD; Matthay, Michael A. MD; Choi, Augustine M. MD; Baron, Rebecca M. MDAuthor Information Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University, Stanford, CA Division of Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, CA Department of Medicine, Cardiovascular Research Institute, University of California, San Francisco, CA, and Department of Anesthesia, Cardiovascular Research Institute, University of California, San Francisco, CA Department of Medicine, Weill Cornell Medicine, New York, NY Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA Drs. Rogers, Choi, and Baron received support for article research from the National Institutes of Health (NIH). Dr. Desai received support for article research from Stanford University Internal Institutional funds. Dr. Matthay’s institution received funding from Department of Defense, NIH, Bayer Pharmaceuticals, and he received funding from GlaxoSmithKline and Cerus Therapeutics. Dr. Choi disclosed that he is a cofounder, stockholder, and serves on the Scientific Advisory Board for Proterris, which develops therapeutic uses for carbon monoxide (CO), and has a use patent on CO. He also served as a consultant for Teva Pharmaceuticals. Dr. Baron’s institution received funding from the NIH; she received funding from Merck; and she disclosed off-label product use of rosuvastatin for infection-related acute respiratory distress syndrome. Critical Care Medicine: January 2020 - Volume 48 - Issue 1 - p e78 doi: 10.1097/CCM.0000000000004081 Buy Metrics Copyright © 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.